Is the Government Supporting Development of India's First Indigenous Thrombectomy Device for Stroke Care?
Click to start listening
Synopsis
India is on the verge of a medical breakthrough with government support for the nation's first indigenous thrombectomy device, potentially revolutionizing stroke care. Discover how this initiative promises to enhance healthcare accessibility and affordability while reducing dependency on imports.
Key Takeaways
- Government support for indigenous medical technology.
- Focus on improving stroke care accessibility.
- Reduction of dependency on imported medical devices.
- Establishment of advanced manufacturing facilities in India.
- Commitment to inclusive healthcare through initiatives like Ayushman Bharat.
New Delhi, May 30 (NationPress) In a major advancement for India’s medical technology sector, the Technology Development Board (TDB), operating under the Union Department of Science and Technology (DST), has officially declared financial backing for the creation of India’s inaugural indigenous thrombectomy device aimed at stroke treatment.
The board has granted assistance to S3V Vascular Technologies, located in Mysuru, for their innovative neuro-intervention integrated manufacturing facility dedicated to stroke management, with nearly 1.5 million cases reported annually in the nation.
This initiative aims to develop a cutting-edge manufacturing plant at the Medical Devices Park in Oragadam, situated in Chennai’s Sriperumbudur region.
The facility will focus on producing and developing advanced mechanical thrombectomy kits, which serve as a crucial intervention for patients experiencing acute ischemic stroke due to large vessel blockage.
In contrast to traditional thrombolysis methods, thrombectomy significantly enhances patient outcomes, decreasing the likelihood of long-term paralysis and disability.
"The TDB is thrilled to back S3V’s ambition of establishing India’s first comprehensive manufacturing ecosystem for neuro-intervention. This initiative underscores our sustained dedication to transforming India into a global center for affordable, high-quality medical technology, particularly in critical health areas such as stroke treatment," stated TDB Secretary Rajesh Kumar Pathak.
"The company’s commitment to integrating these devices within the Ayushman Bharat initiative further supports the national objective of ensuring inclusive healthcare access," he added.
This project will facilitate the replacement of costly imported devices with high-quality, domestically produced options, thereby improving accessibility and affordability for stroke care in India.
“Our integrated manufacturing facility will not only lessen the reliance on imports of finished medical devices for Mechanical Thrombectomy but will also minimize India's dependency on imported raw materials necessary for the production of these vital, complex lifesaving medical devices,” commented Dr. N.G. Vijaya Gopal, Managing Director of S3V Vascular Technologies, expressing gratitude for the government's support.
Dr. Gopal further mentioned that the company has already commenced the CE and US FDA approval processes for the devices to broaden access to advanced stroke care solutions across India, Asia, Latin America, Europe, and the United States.
Point of View
This initiative signifies a vital step towards self-sufficiency in medical technology. By investing in local manufacturing of essential medical devices, India is not only addressing critical public health needs but also positioning itself as a significant player in the global healthcare market. Such developments are essential for enhancing the country's healthcare infrastructure and ensuring that quality care is accessible to all citizens.
NationPress
24/07/2025
Frequently Asked Questions
What is the significance of the indigenous thrombectomy device?
The indigenous thrombectomy device is crucial as it aims to improve stroke care in India by providing an affordable and locally manufactured alternative to expensive imported devices.
How many stroke cases are reported annually in India?
India sees nearly 1.5 million cases of stroke every year, highlighting the urgent need for effective treatment solutions.
Where will the manufacturing facility be located?
The advanced manufacturing facility will be established at the Medical Devices Park in Oragadam, Chennai's Sriperumbudur area.
What are the benefits of thrombectomy over traditional methods?
Thrombectomy significantly enhances patient outcomes by reducing the risks of long-term paralysis and disability compared to conventional thrombolysis methods.
What does the TDB's support signify for India's medtech sector?
The TDB's backing represents a commitment to fostering India's medtech innovation, aiming to make the country a global hub for affordable, high-quality medical technology.
